Estrogen receptor binding results in DCIS

After analyzing samples from a UK / ANZ DCIS randomized trial, the authors found that led by Dr. Mangesh Thorat, PhD, heterogeneity in ER expression in 11% of ER-positive DCIS. Furthermore, they concluded that multiclonal ERs had a greater triple-fold risk of ipsilateral recurrence than ER-negative DCIS. As a result, the researchers said that ER – and its clonality – should be routinely evaluated in DCIS patients.

“A routine study of ER at DCIS will help to avoid both prevention and treatment in this type of breast cancer,” Thorat said in a statement from Queen Mary University in London. this study also contributes to the development of future breast cancer research through the use of new scientific models, particularly in the areas of drug resistance and the use of targeted therapies. “

Copyright © 2021 LabPulse.com

.Source